Do analysts recommend GRTX or CUPR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, GRTX or CUPR?

Cuprina Holdings (Cayman) has higher revenue and earnings than Galera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galera Therapeutics N/A N/A -$59.08M $0.64 0.14 Cuprina Holdings (Cayman) $49.89K 61.65 -$3.63M N/A N/A

Is GRTX or CUPR more profitable?

Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Cuprina Holdings (Cayman) N/A N/A N/A

Do analysts recommend CUPR or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger earnings & valuation, CUPR or BFRI?

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Biofrontera. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 61.65 -$3.63M N/A N/A Biofrontera $43.20M 0.32 -$10.54M -$0.97 N/A

Do analysts rate LEXX or CUPR?

Lexaria Bioscience presently has a consensus target price of $1.50, indicating a potential upside of 168.34%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Cuprina Holdings (Cayman). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, LEXX or CUPR?

Cuprina Holdings (Cayman) has lower revenue, but higher earnings than Lexaria Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexaria Bioscience $194K 71.42 -$11.90M -$0.34 N/A Cuprina Holdings (Cayman) $49.89K 61.65 -$3.63M N/A N/A

Is LEXX or CUPR more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Cuprina Holdings (Cayman) N/A N/A N/A

Do analysts prefer KALA or CUPR?

KALA BIO presently has a consensus target price of $1,158.33, suggesting a potential upside of 182,544.80%. Given KALA BIO's stronger consensus rating and higher possible upside, equities analysts plainly believe KALA BIO is more favorable than Cuprina Holdings (Cayman). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, KALA or CUPR?

Cuprina Holdings (Cayman) has higher revenue and earnings than KALA BIO. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Cuprina Holdings (Cayman) $49.89K 61.65 -$3.63M N/A N/A

Is KALA or CUPR more profitable?

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Cuprina Holdings (Cayman) N/A N/A N/A

Do analysts prefer CUPR or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cuprina Holdings (Cayman) 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, CUPR or AIMD?

Cuprina Holdings (Cayman) has higher revenue and earnings than Ainos. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cuprina Holdings (Cayman) $49.89K 61.65 -$3.63M N/A N/A Ainos $18.11K 658.91 -$14.77M -$2.89 N/A

Cuprina Holdings (Cayman) (CUPR) Competitors

$3.34 +0.03 (+0.91%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$3.22 -0.12 (-3.71%)

As of 07/24/2026 07:34 PM Eastern

Compare

CUPR vs. GRTX, BFRI, LEXX, KALA, and AIMD

Should you buy Cuprina Holdings (Cayman) stock or one of its competitors? MarketBeat compares Cuprina Holdings (Cayman) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cuprina Holdings (Cayman) include Galera Therapeutics (GRTX), Biofrontera (BFRI), Lexaria Bioscience (LEXX), KALA BIO (KALA), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry.

How does Cuprina Holdings (Cayman) compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical preparations industry companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

In the previous week, Cuprina Holdings (Cayman) had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 0 mentions for Galera Therapeutics. Cuprina Holdings (Cayman)'s average media sentiment score of 1.15 beat Galera Therapeutics' score of 0.00 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Cuprina Holdings (Cayman)	Positive

50.8% of Galera Therapeutics shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Galera Therapeutics has a beta of 2.6, suggesting that its stock price is 160% more volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, suggesting that its stock price is 210% less volatile than the broader market.

Cuprina Holdings (Cayman) has higher revenue and earnings than Galera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Cuprina Holdings (Cayman)	$49.89K	61.65	-$3.63M	N/A	N/A

Summary

Cuprina Holdings (Cayman) beats Galera Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Biofrontera?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Biofrontera (NASDAQ:BFRI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 1 mentions for Biofrontera. Cuprina Holdings (Cayman)'s average media sentiment score of 1.15 beat Biofrontera's score of 0.94 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Biofrontera	Positive

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Biofrontera	-25.66%	-515.34%	-53.91%

Cuprina Holdings (Cayman) has a beta of -1.1, meaning that its stock price is 210% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Cuprina Holdings (Cayman) has higher earnings, but lower revenue than Biofrontera.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	61.65	-$3.63M	N/A	N/A
Biofrontera	$43.20M	0.32	-$10.54M	-$0.97	N/A

10.1% of Biofrontera shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cuprina Holdings (Cayman) beats Biofrontera on 7 of the 13 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

13.1% of Lexaria Bioscience shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Lexaria Bioscience had 2 more articles in the media than Cuprina Holdings (Cayman). MarketBeat recorded 4 mentions for Lexaria Bioscience and 2 mentions for Cuprina Holdings (Cayman). Cuprina Holdings (Cayman)'s average media sentiment score of 1.15 beat Lexaria Bioscience's score of 0.63 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Positive
Cuprina Holdings (Cayman)	Positive

Lexaria Bioscience has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, meaning that its stock price is 210% less volatile than the broader market.

Cuprina Holdings (Cayman) has lower revenue, but higher earnings than Lexaria Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$194K	71.42	-$11.90M	-$0.34	N/A
Cuprina Holdings (Cayman)	$49.89K	61.65	-$3.63M	N/A	N/A

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Lexaria Bioscience presently has a consensus target price of $1.50, indicating a potential upside of 168.34%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lexaria Bioscience beats Cuprina Holdings (Cayman) on 9 of the 13 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Cuprina Holdings (Cayman) (NASDAQ:CUPR) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Cuprina Holdings (Cayman) has higher revenue and earnings than KALA BIO.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Cuprina Holdings (Cayman)	$49.89K	61.65	-$3.63M	N/A	N/A

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 1 mentions for KALA BIO. KALA BIO's average media sentiment score of 1.87 beat Cuprina Holdings (Cayman)'s score of 1.15 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Very Positive
Cuprina Holdings (Cayman)	Positive

KALA BIO has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market. Comparatively, Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its share price is 210% less volatile than the broader market.

KALA BIO presently has a consensus target price of $1,158.33, suggesting a potential upside of 182,544.80%. Given KALA BIO's stronger consensus rating and higher possible upside, equities analysts plainly believe KALA BIO is more favorable than Cuprina Holdings (Cayman).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

24.6% of KALA BIO shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cuprina Holdings (Cayman)'s return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Cuprina Holdings (Cayman)	N/A	N/A	N/A

Summary

KALA BIO and Cuprina Holdings (Cayman) tied by winning 6 of the 12 factors compared between the two stocks.

How does Cuprina Holdings (Cayman) compare to Ainos?

Cuprina Holdings (Cayman) (NASDAQ:CUPR) and Ainos (NASDAQ:AIMD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

In the previous week, Cuprina Holdings (Cayman) had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Cuprina Holdings (Cayman) and 1 mentions for Ainos. Cuprina Holdings (Cayman)'s average media sentiment score of 1.15 beat Ainos' score of 0.94 indicating that Cuprina Holdings (Cayman) is being referred to more favorably in the media.

Company	Overall Sentiment
Cuprina Holdings (Cayman)	Positive
Ainos	Positive

Cuprina Holdings (Cayman) has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Cuprina Holdings (Cayman)'s return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cuprina Holdings (Cayman)	N/A	N/A	N/A
Ainos	-11,912.10%	-160.55%	-62.29%

Cuprina Holdings (Cayman) has higher revenue and earnings than Ainos.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cuprina Holdings (Cayman)	$49.89K	61.65	-$3.63M	N/A	N/A
Ainos	$18.11K	658.91	-$14.77M	-$2.89	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cuprina Holdings (Cayman)	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cuprina Holdings (Cayman) has a beta of -1.1, indicating that its share price is 210% less volatile than the broader market. Comparatively, Ainos has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market.

Summary

Cuprina Holdings (Cayman) beats Ainos on 7 of the 9 factors compared between the two stocks.

Get Cuprina Holdings (Cayman) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CUPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CUPR vs. The Competition

Export

Metric	Cuprina Holdings (Cayman)	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.05M	$975.85M	$7.24B	$12.26B
Dividend Yield	N/A	4.84%	40.99%	9.79%
P/E Ratio	N/A	1.53	23.62	23.64
Price / Sales	61.65	104.46	132.14	89.45
Price / Cash	N/A	20.06	165.01	59.64
Price / Book	2.23	8.47	12.77	6.07
Net Income	-$3.63M	-$2.70M	$120.21M	$331.99M
7 Day Performance	-15.87%	-2.29%	-0.98%	-0.63%
1 Month Performance	-40.88%	-3.97%	-2.00%	-2.00%
1 Year Performance	N/A	27.39%	9.75%	13.62%

Cuprina Holdings (Cayman) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CUPR Cuprina Holdings (Cayman)	1.0253 of 5 stars	$3.34 +0.9%	N/A	N/A	$3.05M	$49.89K	N/A	14	Positive News Short Interest Decrease
GRTX Galera Therapeutics	N/A	$0.09 flat	N/A	+272.9%	$14.12M	N/A	N/A	30
BFRI Biofrontera	1.3091 of 5 stars	$1.08 flat	N/A	-1.4%	$13.83M	$41.71M	N/A	70
LEXX Lexaria Bioscience	2.7184 of 5 stars	$0.56 +1.0%	$1.50 +168.1%	-44.7%	$13.73M	$710K	N/A	7	News Coverage Short Interest Decrease Analyst Revision
KALA KALA BIO	2.499 of 5 stars	$0.74 +0.4%	$1,158.33 +157,175.4%	-99.8%	$13.63M	N/A	N/A	30	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CUPR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cuprina Holdings (Cayman) (CUPR) Competitors

CUPR vs. GRTX, BFRI, LEXX, KALA, and AIMD

How does Cuprina Holdings (Cayman) compare to Galera Therapeutics?

Summary

How does Cuprina Holdings (Cayman) compare to Biofrontera?

Summary

How does Cuprina Holdings (Cayman) compare to Lexaria Bioscience?

Summary

How does Cuprina Holdings (Cayman) compare to KALA BIO?

Summary

How does Cuprina Holdings (Cayman) compare to Ainos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUPR vs. The Competition

Cuprina Holdings (Cayman) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cuprina Holdings (Cayman) (CUPR) Competitors

CUPR vs. GRTX, BFRI, LEXX, KALA, and AIMD

How does Cuprina Holdings (Cayman) compare to Galera Therapeutics?

Does the media prefer GRTX or CUPR?

Do insiders and institutionals have more ownership in GRTX or CUPR?

Do analysts recommend GRTX or CUPR?

Is GRTX or CUPR more profitable?

Which has more risk and volatility, GRTX or CUPR?

Which has better earnings and valuation, GRTX or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to Biofrontera?

Do analysts recommend CUPR or BFRI?

Does the media refer more to CUPR or BFRI?

Is CUPR or BFRI more profitable?

Which has more volatility and risk, CUPR or BFRI?

Which has stronger earnings & valuation, CUPR or BFRI?

Do institutionals & insiders hold more shares of CUPR or BFRI?

Summary

How does Cuprina Holdings (Cayman) compare to Lexaria Bioscience?

Do insiders & institutionals hold more shares of LEXX or CUPR?

Does the media prefer LEXX or CUPR?

Which has more risk and volatility, LEXX or CUPR?

Which has higher valuation and earnings, LEXX or CUPR?

Is LEXX or CUPR more profitable?

Do analysts rate LEXX or CUPR?

Summary

How does Cuprina Holdings (Cayman) compare to KALA BIO?

Which has preferable valuation & earnings, KALA or CUPR?

Does the media prefer KALA or CUPR?

Which has more risk and volatility, KALA or CUPR?

Do analysts prefer KALA or CUPR?

Do institutionals & insiders have more ownership in KALA or CUPR?

Is KALA or CUPR more profitable?

Summary

How does Cuprina Holdings (Cayman) compare to Ainos?

Does the media prefer CUPR or AIMD?

Is CUPR or AIMD more profitable?

Which has higher earnings and valuation, CUPR or AIMD?

Do analysts prefer CUPR or AIMD?

Which has more risk & volatility, CUPR or AIMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CUPR vs. The Competition

Cuprina Holdings (Cayman) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools